Stockscreener 앱 받기
6.81
9.56%
-0.72
시간 외 거래:
6.81
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics 10-K: $0 Revenue, $(0.00) EPS, $(43.4M) Net Loss - TradingView
Kalaris Therapeutics (NASDAQ: KLRS) builds TH103 pipeline in retinal disease - Stock Titan
Kalaris Therapeutics Reports 2025 Financial Results, Highlights Positive TH103 nAMD Phase 1a Data and Strong Cash Position - Minichart
Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates - Investing News Network
KLRS: Strong clinical progress and $118M cash position support operations through 2027 - TradingView
Kalaris (Nasdaq: KLRS) trims 2025 loss as $118M cash funds TH103 trials - Stock Titan
Retinal drug developer Kalaris posts $43M loss, funded into late 2027 - Stock Titan
Kalaris Therapeutics (NASDAQ:KLRS) Raised to "Hold" at Wall Street Zen - MarketBeat
Raymond James Maintains Strong Buy on KLRS Kalaris Therapeutics Inc Mar 2026 - Meyka
William Blair reiterates Kalaris stock rating on TH103 potential By Investing.com - Investing.com Canada
Kalaris Therapeutics TH103: Next-Generation Anti-VEGF for Retinal Diseases Shows Promising Phase 1a Results and Extended Durability 23578 - Minichart
Stock Market Recap: Can Kalaris Therapeutics Inc weather a recessionPortfolio Risk Report & Weekly Return Optimization Plans - baoquankhu1.vn
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay By Investing.com - Investing.com Canada
Raymond James reiterates Strong Buy on Kalaris stock amid trial delay - Investing.com UK
Kalaris Updates TH103 Strategy and Highlights Cash Runway - TipRanks
Kalaris updates TH103 timelines, previews Phase 1b/2 data and extends cash runway into Q4 2027 - TradingView
Aug Analyst Calls: Is Kalaris Therapeutics Inc stock a good pick for beginners2026 PreEarnings & Precise Buy Zone Tips - baoquankhu1.vn
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Will Kalaris Therapeutics Inc. stock benefit from green energy trendsQuarterly Trade Report & Fast Exit and Entry Strategy Plans - Naître et grandir
Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen - MarketBeat
US Market Wrap: Is Kalaris Therapeutics Inc vulnerable to short sellersJuly 2025 Fed Impact & Short-Term Trading Alerts - baoquankhu1.vn
Jeffrey Bornstein - ProPublica
KLRS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Kalaris Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
KLRS Should I Buy - Intellectia AI
Published on: 2026-02-28 06:52:09 - baoquankhu1.vn
ETFs Investing in Kalaris Therapeutics, Inc. Stocks - TradingView
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold - MarketBeat
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therape - GuruFocus
RTW INVESTMENTS, LP Acquires 1,300,000 Shares in Kalaris Therapeutics Inc - GuruFocus
Sell Signal: Is CRISPR Therapeutics AG backed by strong institutional buyingGold Moves & Growth Focused Entry Point Reports - baoquankhu1.vn
Insider Stock Purchases: February 18, 2026 - Quiver Quantitative
Kalaris Therapeutics Insider Bought Shares Worth $5,000,006, According to a Recent SEC Filing - marketscreener.com
Kalaris Therapeutics (NASDAQ:KLRS) Director Acquires $5,000,005.74 in Stock - MarketBeat
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares By Investing.com - Investing.com South Africa
Kalaris Therapeutics: Samsara Opportunity fund buys $5m in shares - Investing.com Australia
Akkaraju group reports 56.5% Kalaris (KLRS) ownership stake - Stock Titan
RTW discloses 5.7% Kalaris Therapeutics (KLRS) ownership stake - Stock Titan
Earnings Miss: How Kalaris Therapeutics Inc. stock compares to industry benchmarksJuly 2025 Action & Weekly Market Pulse Alerts - mfd.ru
Is Kalaris Therapeutics Inc. undervalued by DCF analysisSwing Trade & Capital Efficiency Focused Ideas - mfd.ru
Will Kalaris Therapeutics Inc. benefit from rate cutsJuly 2025 News Drivers & Fast Gain Stock Tips - mfd.ru
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why Kalaris Therapeutics Inc. stock is trending among retail tradersQuarterly Investment Review & High Return Trade Opportunity Guides - mfd.ru
Kalaris Therapeutics Emerges with Focused Retinal Disease Strategy - AD HOC NEWS
Institution Moves: Whats the profit margin of Kalaris Therapeutics IncTrade Exit Report & Risk Adjusted Buy/Sell Alerts - baoquankhu1.vn
Short Interest in Kalaris Therapeutics Inc. (NASDAQ:KLRS) Increases By 60.8% - MarketBeat
Kalaris Therapeutics (NASDAQ:KLRS) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat
Smart Money: Should I add Kalaris Therapeutics Inc stock to my portfolioJuly 2025 Big Picture & Real-Time Buy Signal Notifications - baoquankhu1.vn
Kalaris to present phase 1 data of novel eye therapy at Macula Society - Investing.com Australia
Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting - Investing News Network
1.20%
0.06%
자본화:
|
볼륨(24시간):